Randomized controlled trials are needed to find whether LVH, cardiac fibrosis, and electrical instability that plague patients with CKD can be prevented by aggressive multifactorial therapy started early in CKD, possibly including therapeutic lowering of PlGF, FGF23 or EN-RAGE levels. Here, FGF23 is linked to chronic kidney disease.